Streptokinase versus Alteplase in Acute Myocardial Infarction

The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Mel 1993; 329: 673–82

The GUSTO Angiographic Investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med 1993; 329: 1615–22

Chesebro J.H. , Knatterud G. , Roberts R. Thrombolysis in Myocardial Infarction (TIMI) trial, phase I: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Circulation 1987; 71: 142–54

Gruppo Italiano Per lo Studio Delia Sopravvivenza Nell’ Infarto Miocardico. GISSI-2: A factorial randomized trial of alteplase versus streptokinase and heparin versus no heparin among 12 490 patients with acute myocardial infarction. Lancet 1990; 336: 65–71

The International Study Group. In-hospital mortality and clinical course of 20891 patients with suspected acute myocardial infarction randomized between alteplase and streptokinase with or without heparin. Lancet 1990; 336: 71–5

ISIS-3: Third International Study Infarct Survival Collaborative Group. ISIS-3: a randomized comparison of streptokinase versus tissue plasminogen activator versus anistreplase and of aspirin plus heparin versus aspirin alone among 41 299 cases of suspected acute myocardial infarction. Lancet 1992; 339: 753–70

Lew A.S. , Laramee P. , Cercek B. , Rodriguez L. , Prediman K.S. , Ganz W. . The effects of the rate of intravenous infusion of streptokinase and the duration of symptoms on the time interval to reperfusion in patients with acute myocardial infarction. Circulation 1985; 72: 1053–8

White H.D. , Norris R.M. , Brown M.A. Effect of intravenous streptokinase on left ventricular function and early survival after acute myocardial infarction. N Engl] Med 1987; 317: 850–5

Bleich S.D. , Nicholas T.C. , Schumacher R.R. , Cooke D.H. , Tate D.A. , Teichman S.L. . Effect of heparin on coronary arterial patency after thrombolysis with tissue plasminogen activator in acute myocardial infarction. Am J Cardiol 1990; 66: 1412–17

de Bono D.P. , Simoons M.L. , Tijssen J. Effect of early intravenous heparin on coronary patency, infarct size, and bleeding complications after alteplase thrombolysis: results of a randomized double blind European Cooperative Study Group trial. Br Heart J 1992; 67: 122–8

Hsia J. , Hamilton W.P. , Kleiman N. , Roberts R. , Chairman B.R. , Ross A.M. . A comparison between heparin and low-dose aspirin as adjunctive therapy with tissue plasminogen activator for acute myocardial infarction. N Engl J Med 1990; 323: 1433–7

Topol E.J. , George B.S. , Kereiakes D.J. A randomized controlled trial of intravenous tissue plasminogen activator and early intravenous heparin in acute myocardial infarction. Circulation 1989; 79: 281–6

Kleiman N.S. , White H.D. , Ohman M. Mortality within 24-hours of thrombolysis for myocardial infarction. The importance of early reperfusion. Circulation 1994; 90: 1658–65

Simes R.J. , Topol E.J. , Holmes D.R. Link between the angiographic substudy and mortality outcomes in a large randomized trial of myocardial reperfusion. Circulation 1995; 91: 1923–8

The GUSTO Investigators. More on the GUSTO Trial. N Engl J Med 1994; 331: 277–8

Mark D.B. , Naylor C.D. , Mark D. Use of medical resources and quality of life after acute myocardial infarction in Canada and the United States. N Engl J Med 1994; 331: 1130–5

Lee K.L. , Woodlief L.H. , Topol E.J. , Weaver D. , Betriu A. . Predictor of 30-day mortality in the era of reperfusion for acute myocardial infarction. Circulation 1995; 91: 1659–68

Van de Werf F.V. , Topol E.J. , Lee K.L. Variations in patient management and outcomes for acute myocardial infarction in the United States and other countries. JAMA 1995; 273: 1586–91

Ridker P.M. , Marder V.J. , Hennekens C.H. . Large-scale trial of thrombolytic therapy for acute myocardial infarction: GISSI-2, ISIS-3, and GUSTO-1. Ann Intern Med 1993; 119: 530–2

Ridker P.M. , O'Donnell C.J. , Marder V.J. , Hennekens C.H. . A response to ‘holding GUSTO up to the light’. Ann Intern Med 1994; 120: 882–5

Hennekens C.H. . Thrombolytic therapy: pre- and post-GISSI-2, and GUSTO-1. Clin Cardiol 1994; 17(suppl I): 1-15–1-17

Herman J. . The demise of the randomized controlled tiral. J Clin Epidemiol 1995; 48: 985–8

Lee K.L. , Califf R.M. , Simes J. , Van de Werf F. , Topol E. . Holding GUSTO up to the light. Ann Intern Med 1994; 120: 876–81

Simoons M.L. , Betriu A. , Col J. Thrombolysis with tissue plasminogen activator in acute myocardial infarction: No additional benefit from immediate percutaneous coronary angioplasty. Lancet 1988; i: 197–202

The TIMI Research Group. Immediate versus delayed catheterization and angioplasty following thrombolytic therapy for acute myocardial infarction. TIMI II A Results: JAMA 1988; 260: 2849–58

The TIMI Study Group. Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) Phase II Trial. N Engl J Med 1989; 320: 618–27

Fibrinolytic Therapy Trialists Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomized trials of more than 1000 patients. Lancet 1994; 343: 311–22

Reimer K.A. , Jennings R.B. . The ‘Wavefront phenomenon’ of myocardial ischemic cell death. II Transmural progression of necrosis within the framework of ischemic bed size (myocardium at risk) and collateral flow. Lab Invest 1979; 40: 633–44

Kloner R.A. , Ellis S.G. , Lange R. , Braunwald E. . Studies of experimental coronary artery reperfusion: effects on infarct size, myocardial function, biochemistry, ultrastructure and microvascular damage. Circulation 1983; 68(suppl I): I-8–I-15

LATE Study Group. Late Assessment of Thrombolytic Efficacy (LATE) study with alteplase 6–24 hours after onset of acute myocardial infarction. Lancet 1993; 342: 759–66

ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomized trial of intravenous streptokinase, oral aspirin, both or neither among 17187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988; ii: 349–6